Reference
1. Tan A, Bieber AK, Stein JA and Pomeranz MK: Diagnosis and management of vulvar cancer: A review. J Am Acad Dermatol 81: 1387-1396, 2019.
2. Survival rates for vulvar cancer. American cancer societyhttps://wwwcancerorg/cancer/vulvar-cancer/detection-diagnosis-staging/survival-rateshtmlRevised on Feb 4th, 2019.
3. Couzin-Frankel J: Breakthrough of the year 2013. Cancer immunotherapy. Science 342: 1432-1433, 2013.
4. June CH, O’Connor RS, Kawalekar OU, Ghassemi S and Milone MC: CAR T cell immunotherapy for human cancer. Science 359: 1361-1365, 2018.
5. Nobbenhuis MA, Lalondrelle S, Larkin J and Banerjee S: Management of melanomas of the gynaecological tract. Curr Opin Oncol 26: 508-513, 2014.
6. Sznurkowski JJ, Zawrocki A, Emerich J and Biernat W: Prognostic significance of CD4+ and CD8+ T cell infiltration within cancer cell nests in vulvar squamous cell carcinoma. Int J Gynecol Cancer 21: 717-721, 2011.
7. Kortekaas KE, Santegoets SJ, Abdulrahman Z, et al : High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status. J Immunother Cancer 7: 236, 2019.
8. Geukes Foppen MH, Donia M, Svane IM and Haanen JB: Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Mol Oncol 9: 1918-1935, 2015.
9. Bedognetti D, Spivey TL, Zhao Y, et al : CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer 109: 2412-2423, 2013.
10. Mikucki ME, Fisher DT, Matsuzaki J, et al : Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun 6: 7458, 2015.
11. Rosenberg SA, Packard BS, Aebersold PM, et al : Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676-1680, 1988.
12. Creelan B, Wang C, Teer J, et al : Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial. Cancer Research 80: CT056-CT056, 2020.
13. Tran E, Robbins PF, Lu YC, et al : T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med 375: 2255-2262, 2016.
14. Zacharakis N, Chinnasamy H, Black M, et al : Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 24: 724-730, 2018.
15. Jazaeri AA, Zsiros E, Amaria RN, et al : Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. Journal of Clinical Oncology 37: 2538-2538, 2019.
16. Bolotin DA, Poslavsky S, Mitrophanov I, et al : MiXCR: software for comprehensive adaptive immunity profiling. Nature Methods 12: 380-381, 2015.
17. Powell DJ, Jr., Dudley ME, Robbins PF and Rosenberg SA: Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105: 241-250, 2005.
18. Datar I, Sanmamed MF, Wang J, et al : Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clin Cancer Res 25: 4663-4673, 2019.
19. Jansen CS, Prokhnevska N, Master VA, et al : An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576: 465-470, 2019.
20. Chen L and Han X: Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125: 3384-3391, 2015.
21. Siddiqui I, Schaeuble K, Chennupati V, et al : Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity 50: 195-211 e110, 2019.
22. Utzschneider DT, Charmoy M, Chennupati V, et al : T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. Immunity 45: 415-427, 2016.
23. Duhen T, Duhen R, Montler R, et al : Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun 9: 2724, 2018.
24. Ribas A and Wolchok JD: Cancer immunotherapy using checkpoint blockade. Science 359: 1350-1355, 2018.
25. Gros A, Parkhurst MR, Tran E, et al : Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nature medicine 22: 433-438, 2016.
26. Crane CA, Han SJ, Ahn B, et al : Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. 19: 205-214, 2013.
27. Turcotte S, Gros A, Hogan K, et al : Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol 191: 2217-2225, 2013.